Keyword: CDMO

Gilead oncology EVP Riva joins Glenmark spinoff as CEO; Biocon's biosimilar plant dinged by FDA; Shionogi licenses Akili's digital therapeutics.

Takeda's dengue vaccine clears phase 3; Pfizer launches China's first pay-for-performance deal in oncology; Aslan cuts 30% of its workforce.

Sun Pharma drops to six-year low; Takeda looks to sell emerging markets products; Immunochina raises $20 million for CAR-T push.

WuXi Biologics is forming a human vaccine-focused CDMO joint venture with local veterinary vaccine firm Shanghai Hile Bio-Technology.

The North American expansions come amid a restructuring at Evonik, which aims to save €200 million in cost by the end of 2020.

The FDA hit Ei with a warning letter outlining poor manufacturing procedures at the company’s facility in Kannapolis, North Carolina.

CMAB Biopharma snagged $34 million in series B financing the company said will be used to upgrade and expand its manufacturing plant.

South Korea’s Hanmi Pharmaceutical expects growth from its $140 million smart drug manufacturing facility in its move toward the CDMO market.

3P Biopharmaceuticals, a Spanish CDMO, has inked a deal with Intervacc to produce the company’s Strangvac equine vaccine to treat strangles.

iBio, a CDMO that focuses on plant-based biotechnology, said it reached an agreement to support Aethlon Medical with the production of its blood purification device.